Dr. Schoenbeck is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
400 Parnassus Ave
San Francisco, CA 94143Phone+1 415-353-2421
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2021- University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2017 - 2020
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2012 - 2015
Oregon Health and Science University School of MedicineClass of 2012, MD
Certifications & Licensure
CA State Medical License 2015 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice.Matthew J Pianko, Hira S Mian, Kelly L Schoenbeck, Tanya M Wildes
Leukemia & Lymphoma. 2024-10-28 - 1 citationsValue of embedded palliative care: outpatient palliative care and health care utilization for patients with hematologic malignancies.Mazie Tsang, Kara Bischoff, Kelly L Schoenbeck, Kim Berry, David O'Riordan
Blood Advances. 2023-07-11 - Where the Sidewalk Ends: Parenting as a Trainee during COVID-19.Mazie Tsang, Rahul Banerjee, Dionisia Quiroga, Dame Idossa, Kelly L Schoenbeck
Cancer Investigation. 2023-07-01
Abstracts/Posters
- Cognitive Dysfunction Associated with Tyrosine Kinase Inhibitors in Patients with CML in Chronic PhaseKelly L. Schoenbeck, MD, Sirisha Tummala, MD, Neha G. Goyal, PhD, Catherine C. Smith, MD and Neil P. Shah, MD, PhD, 62nd American Society of Hematology Annual Meeting & Exposition, 12/6/2020
- Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative NeoplasmsKelly L. Schoenbeck, MD , Giselle Salmasi, MD , Miguel Carlos Cerejo, DO , Patricia A. Cornett, MD , Lloyd E. Damon, MD , Aaron C. Logan, MD PhD , Rebecca L. Olin, MD ..., 61st American Society of Hematology Annual Meeting & Exposition, Orlando, FL, 12/7/2019
Press Mentions
Clinical Challenges: Discontinuing TKIs in Chronic Myeloid LeukemiaDecember 11th, 2020
Program Chairs Pick Their Top ASH HighlightsDecember 1st, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
